摘要
川崎病（Kawasaki disease，KD）是一种以急性全身血管炎为主要病理变化的疾病，好发于6个月-4岁的婴幼儿。如果未经正规治疗，25％～30％的患儿会出现冠状动脉病变，而早期大剂量的静脉用丙种球蛋白（IVIG）能显著减低冠状动脉瘤的发生率。临床上将IVIG联合阿司匹林作为治疗KD的常规药物，然而一部分患者对IVIG的治疗不敏感仍旧是困扰儿科医师的难题。随着研究的不断深入，很多学者发现联合应用糖皮质激素、TNF-d抑制剂及钙调神经磷酸酶抑制剂等二、三线药物疗效更好，且能有效降低并发症发生率。现就近年来在KD治疗方面取得的最新进展作一综述。
Kawasaki disease （KD） is an acute systemic vasculitis that primarily affects young children aged from 6 months to 4 years. KD may lead to coronary artery abnormalities in 25% -30% of the children. The timely use of high dose intravenous immunoglobulin （IVIC） can significantly reduce the incidence of coronary artery aneurysms. Most clinicians use IVIG combined with aspirin as conventional therapy. But how to deal with those IVIG-resistant pa- tients is a dilemma. With the deepening of research, many researchers have found that some second-line or third-line drugs such as corticosteroids, tumor necrosis factor-α inhibitors, and calcineurin inhibitors work better, and can effec- tively reduce the complication rate. The recent advances of the treatment of KD were summarized in this paper.
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2014年第9期707-709,共3页
Chinese Journal of Applied Clinical Pediatrics
关键词
川崎病
治疗
静脉用丙种球蛋白
Kawasaki disease
Treatment
Intravenous immunoglobulin
